{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T09:36:44Z","timestamp":1748511404265,"version":"3.37.3"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T00:00:00Z","timestamp":1666742400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T00:00:00Z","timestamp":1666742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Eisai Inc., Nutley, NJ, USA"},{"name":"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s00280-022-04480-w","type":"journal-article","created":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T17:02:43Z","timestamp":1666803763000},"page":"523-529","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A feasibility study of lenvatinib plus pembrolizumab in Japanese patients with advanced solid tumors"],"prefix":"10.1007","volume":"90","clinical-trial-number":[{"clinical-trial-number":"nct03006887","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4041-8298","authenticated-orcid":false,"given":"Shigehisa","family":"Kitano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshio","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Iwasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kan","family":"Yonemori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunsuke","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiko","family":"Shimomura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takafumi","family":"Koyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Ebata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Ikezawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nozomi","family":"Hayata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukinori","family":"Minoshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuma","family":"Miura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoki","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noboru","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,10,26]]},"reference":[{"key":"4480_CR1","doi-asserted-by":"publisher","first-page":"5459","DOI":"10.1158\/1078-0432.CCR-07-5270","volume":"14","author":"J Matsui","year":"2008","unstructured":"Matsui J, Funahashi Y, Uenaka T, Watanabe T, Tsuruoka A, Asada M (2008) Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res 14:5459\u20135465. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-5270","journal-title":"Clin Cancer Res"},{"key":"4480_CR2","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/ijc.23131","volume":"122","author":"J Matsui","year":"2008","unstructured":"Matsui J, Yamamoto Y, Funahashi Y, Tsuruoka A, Watanabe T, Wakabayashi T, Uenaka T, Asada M (2008) E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer 122:664\u2013671. https:\/\/doi.org\/10.1002\/ijc.23131","journal-title":"Int J Cancer"},{"key":"4480_CR3","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/638747","volume":"2014","author":"O Tohyama","year":"2014","unstructured":"Tohyama O, Matsui J, Kodama K, Hata-Sugi N, Kimura T, Okamoto K, Minoshima Y, Iwata M, Funahashi Y (2014) Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res 2014:638747. https:\/\/doi.org\/10.1155\/2014\/638747","journal-title":"J Thyroid Res"},{"key":"4480_CR4","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1406470","volume":"372","author":"M Schlumberger","year":"2015","unstructured":"Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff AO, Gianoukakis AG, Kiyota N, Taylor MH, Kim SB, Krzyzanowska MK, Dutcus CE, de las Heras B, Zhu J, Sherman SI (2015) Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 372:621\u2013630. https:\/\/doi.org\/10.1056\/NEJMoa1406470","journal-title":"N Engl J Med"},{"key":"4480_CR5","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL (2018) Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391:1163\u20131173. https:\/\/doi.org\/10.1016\/S0140-6736(18)30207-1","journal-title":"Lancet"},{"key":"4480_CR6","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1016\/S1470-2045(15)00290-9","volume":"16","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Hutson TE, Glen H, Michaelson MD, Molina A, Eisen T, Jassem J, Zolnierek J, Maroto JP, Mellado B, Melichar B, Tomasek J, Kremer A, Kim HJ, Wood K, Dutcus C, Larkin J (2015) Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol 16:1473\u20131482. https:\/\/doi.org\/10.1016\/S1470-2045(15)00290-9","journal-title":"Lancet Oncol"},{"key":"4480_CR7","unstructured":"Eisai Co., Ltd., MSD K.K. (March 23, 2021) Lenvima\u00ae (lenvatinib) approved for additional indication of unresectable thymic carcinoma in Japan [press release]. https:\/\/www.eisai.com\/news\/2021\/news202120.html. Accessed 28 July 2021"},{"key":"4480_CR8","unstructured":"Keytruda\u00ae (pembrolizumab) [package insert] (2021). Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA"},{"key":"4480_CR9","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1200\/JCO.19.01598","volume":"38","author":"MH Taylor","year":"2020","unstructured":"Taylor MH, Lee CH, Makker V, Rasco D, Dutcus CE, Wu J, Stepan DE, Shumaker RC, Motzer RJ (2020) Phase IB\/II trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid tumors. J Clin Oncol 38:1154\u20131163. https:\/\/doi.org\/10.1200\/JCO.19.01598","journal-title":"J Clin Oncol"},{"key":"4480_CR10","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1200\/JCO.19.02627","volume":"38","author":"V Makker","year":"2020","unstructured":"Makker V, Taylor MH, Aghajanian C, Oaknin A, Mier J, Cohn AL, Romeo M, Bratos R, Brose MS, DiSimone C, Messing M, Stepan DE, Dutcus CE, Wu J, Schmidt EV, Orlowski R, Sachdev P, Shumaker R, Casado Herraez A (2020) Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer. J Clin Oncol 38:2981\u20132992. https:\/\/doi.org\/10.1200\/JCO.19.02627","journal-title":"J Clin Oncol"},{"key":"4480_CR11","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","volume":"384","author":"R Motzer","year":"2021","unstructured":"Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T, Gr\u00fcnwald V, Hutson TE, Kopyltsov E, M\u00e9ndez-Vidal MJ, Kozlov V, Alyasova A, Hong SH, Kapoor A, Alonso Gordoa T, Merchan JR, Winquist E, Maroto P, Goh JC, Kim M, Gurney H, Patel V, Peer A, Procopio G, Takagi T et al (2021) Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med 384:1289\u20131300. https:\/\/doi.org\/10.1056\/NEJMoa2035716","journal-title":"N Engl J Med"},{"key":"4480_CR12","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1056\/NEJMoa2108330","volume":"386","author":"V Makker","year":"2022","unstructured":"Makker V, Colombo N, Casado Herr\u00e1ez A, Santin AD, Colomba E, Miller DS, Fujiwara K, Pignata S, Baron-Hay S, Ray-Coquard I, Shapira-Frommer R, Ushijima K, Sakata J, Yonemori K, Kim YM, Guerra EM, Sanli UA, McCormack MM, Smith AD, Keefe S, Bird S, Dutta L, Orlowski RJ, Lorusso D, Study 309\u2013KEYNOTE-775 Investigators (2022) Lenvatinib plus pembrolizumab for advanced endometrial cancer. N Engl J Med 386:437\u2013448. https:\/\/doi.org\/10.1056\/NEJMoa2108330","journal-title":"N Engl J Med"},{"key":"4480_CR13","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1007\/s00280-015-2899-0","volume":"76","author":"S Nakamichi","year":"2015","unstructured":"Nakamichi S, Nokihara H, Yamamoto N, Yamada Y, Honda K, Tamura Y, Wakui H, Sasaki T, Yusa W, Fujino K, Tamura T (2015) A phase 1 study of lenvatinib, multiple receptor tyrosine kinase inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 76:1153\u20131161. https:\/\/doi.org\/10.1007\/s00280-015-2899-0","journal-title":"Cancer Chemother Pharmacol"},{"key":"4480_CR14","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1038\/bjc.2012.154","volume":"106","author":"DS Boss","year":"2012","unstructured":"Boss DS, Glen H, Beijnen JH, Keesen M, Morrison R, Tait B, Copalu W, Mazur A, Wanders J, O\u2019Brien JP, Schellens JH, Evans TR (2012) A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours. Br J Cancer 106:1598\u20131604. https:\/\/doi.org\/10.1038\/bjc.2012.154","journal-title":"Br J Cancer"},{"issue":"15","key":"4480_CR15","doi-asserted-by":"publisher","first-page":"5597","DOI":"10.1200\/JCO.2018.36.15_suppl.5597","volume":"36","author":"V Makker","year":"2018","unstructured":"Makker V, Cohn AL, Taylor MH, Minoshima Y, Kato Y, Dairiki R, Kanekiyo M, Yachie A, Kodama K, Sachdev P, Matsui J, Funahashi Y, Rasco DW (2018) Biomarker results and preclinical rationale for combination lenvatinib and pembrolizumab in advanced endometrial carcinoma [abstract]. J Clin Oncol 36(15):5597. https:\/\/doi.org\/10.1200\/JCO.2018.36.15_suppl.5597","journal-title":"J Clin Oncol"},{"issue":"Suppl 4","key":"4480_CR16","doi-asserted-by":"publisher","first-page":"S564","DOI":"10.1016\/j.annonc.2020.08.791","volume":"31","author":"C-H Lee","year":"2020","unstructured":"Lee C-H, Adachi Y, Ikezawa H, Li SD, Funahashi Y, Minoshima Y, Kubiak P, Perini R, Ren M, Smith AD, Motzer RJ (2020) Correlative serum biomarker analyses: lenvatinib (LEN) plus pembrolizumab (PEMBRO) in a phase Ib\/II trial in advanced renal cell carcinoma (RCC) [abstract]. Ann Oncol 31(Suppl 4):S564\u2013S564. https:\/\/doi.org\/10.1016\/j.annonc.2020.08.791 (Abstract 719P)","journal-title":"Ann Oncol"},{"key":"4480_CR17","doi-asserted-by":"publisher","first-page":"7451","DOI":"10.1158\/1078-0432.CCR-11-1747","volume":"17","author":"KB Kim","year":"2011","unstructured":"Kim KB, Chesney J, Robinson D, Gardner H, Shi MM, Kirkwood JM (2011) Phase I\/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma. Clin Cancer Res 17:7451\u20137461. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-1747","journal-title":"Clin Cancer Res"},{"key":"4480_CR18","doi-asserted-by":"publisher","first-page":"637","DOI":"10.2217\/fon-2020-0937","volume":"17","author":"MH Taylor","year":"2021","unstructured":"Taylor MH, Schmidt EV, Dutcus C, Pinheiro EM, Funahashi Y, Lubiniecki G, Rasco D (2021) The LEAP program: lenvatinib plus pembrolizumab for the treatment of advanced solid tumors. Future Oncol 17:637\u2013648. https:\/\/doi.org\/10.2217\/fon-2020-0937","journal-title":"Future Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-022-04480-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-022-04480-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-022-04480-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,5]],"date-time":"2022-11-05T10:09:22Z","timestamp":1667642962000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-022-04480-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,26]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["4480"],"URL":"https:\/\/doi.org\/10.1007\/s00280-022-04480-w","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"type":"print","value":"0344-5704"},{"type":"electronic","value":"1432-0843"}],"subject":[],"published":{"date-parts":[[2022,10,26]]},"assertion":[{"value":"26 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Shigehisa Kitano reports remuneration from ImmuniT Research Inc; honoraria from Ono Pharmaceutical, Bristol Myers Squibb, Astra Zeneca, Chugai, MSD, and Pfizer; and research funds from Eisai, REGENERON, Boehringer Ingelheim, Astellas Pharma, Gilead Sciences, Daiichi Sankyo, Takara Bio, Ono Pharmaceutical, PACT Pharma, Chugai, and MSD. Yutaka Fujiwara reports research funding from Bristol-Myers Squibb and Chugai; and honoraria from Astra Zeneca, Chugai, Daiichi Sankyo, Novartis, ONO Pharmaceutical, Otsuka Pharmaceutical, and Pfizer, outside the submitted work. Toshio Shimizu reports research funds from Novartis, Eli Lilly, Daiichi-Sankyo, Bristol Myers Squibb, AbbVie, Eisai, AstraZeneca, Takeda Oncology, Incyte, Chordia Therapeutics, 3D-Medicine, Symbio Pharmaceuticals, PharmaMar, Pfizer, Five Prime and Astellas Pharma. Satoru Iwasa has nothing to disclose. Kan Yonemori reports lecture fees from Eisai, Taiho, Pfizer, Eli Lilly, AstraZeneca, Takeda, Fuji Film, and Chugai; is an advisor for Takeda, Eisai, Novartis, Chugai, Ono, and AstraZeneca; has received grants for clinical trials from MSD, Daiichi-Sankyo, AstraZeneca, Taiho, Pfizer, Novartis, Takeda, Chugai, Ono, Sanofi, Eisai, Eli Lilly, Genmab, Boehringer Ingelheim, Kyowa Hakko Kirin, and Nihon Kayaku. Shunsuke Kondo has nothing to disclose. Akihiko Shimomura reports honoraria from Chugai Pharmaceutical and Eli-Lilly Japan, and research funds from Chugai Pharmaceutical, AstraZeneca, Daiichi Sankyo, and Taiho Pharmaceutical. Takafumi Koyama reports honoraria from Sysmex. Takahiro Ebata has nothing to disclose. Hiroki Ikezawa is an employee of Eisai Co., Ltd. Nozomi Hayata is an employee of Eisai Co., Ltd. Yukinori Minoshima is an employee of Eisai Co., Ltd. Tomoki Kubota is an employee of Eisai Co., Ltd. Takuma Miura is an employee of Eisai Co., Ltd. Noboru Yamamoto reports honoraria from Chugai, Pfizer and Sysmex; and research funds from Astellas, Chugai, Eisai, Taiho, BMS, Pfizer, Novartis, Eli Lilly, AbbVie, Daiichi-Sankyo, Bayer, Boehringer Ingelheim, Kyowa-Hakko Kirin, Takeda, ONO, Janssen Pharma, MSD, MERCK, GSK, Sumitomo Dainippon, Chiome Bioscience, Otsuka, Carna Biosciences, and Genmab.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol was approved by relevant institutional review boards and conducted in accordance with the principles of the World Medical Association Declaration of Helsinki and Japan\u2019s Good Clinical Practice. The protocol, informed consent form, and appropriate related documents were reviewed by the Institutional Review Board of National Cancer Center, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}